"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a ...

Andrew Berens, an analyst from Leerink Partners, assigned the Buy rating on Cullinan Management (CGEM – Research Report). The associated price ...

Credit: Komsan Loonprom / Shutterstock. Imvax has received $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its autologous biologic-device combination ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142 ...

Veru (VERU) announced positive topline results from the Phase 2b QUALITY clinical study. The Phase 2b QUALITY clinical study was ...

GH Research PLC will host a conference call on February 3, 2025, to discuss Phase 2b trial data for GH001. GH Research PLC announced that it will hold a conference call and live webcast on ...

placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available ...

placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under ...